MGMA

MEDICAL

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

RESEARCH

Samsung Biologics | July 21, 2021

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

CELL AND GENE THERAPY

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Cardiff Oncology | May 27, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...